Evidence-based best practices for EGFR T790M testing in lung cancer in Canada

Current oncology

S. Kamel-Reid²  A. Spatz³  C.A. Souza⁵  M.S. Tsao⁶  A. Karsan⁸  P.K. Cheema⁹  T. Stockley^1,10  B. Melosky^1,11 

[1] McGill University;University of Toronto;Princess Margaret Cancer Centre;University of British Columbia;University of Toronto;BC Cancer;BC Cancer Research Centre;McGill University Health Centre;The Ottawa Hospital;University Health Network;William Osler Health System

关键词: Non-small-cell lung cancer;    nsclc;    epidermal growth factor receptor;    EGFR T790M;    cell-free tumour dna;    ctdna;   

DOI  :  10.3747/co.25.4044

学科分类：肿瘤学

来源: Multimed, Inc.

【 摘 要 】

Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors (tkis) are recommended as first-line systemic therapy for patients with non-small-cell lung cancer (nsclc) having mutations in theEGFRgene. Resistance to tkis eventually occurs in all nsclc patients treated with such drugs. In patients with resistance to tkis caused by theEGFRT790M mutation, the third-generation tki osimertinib is now the standard of care. For optimal patient management, accurateEGFRT790M testing is required. A multidisciplinary working group of pathologists, laboratory medicine specialists, medical oncologists, a respirologist, and a thoracic radiologist from across Canada was convened to discuss best practices forEGFRT790M mutation testing in Canada. The group made recommendations in the areas of the testing algorithm and the pre-analytic, analytic, and post-analytic aspects of clinical testing for both tissue testing and liquid biopsy circulating tumour dna testing. The recommendations aim to improveEGFRT790M testing in Canada and to thereby improve patient care.

【 授权许可】

Unknown